Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1

Nonalcoholic fatty liver disease (NAFLD) is recognized as a metabolic disease characterized by hepatic steatosis. Despite the growing burden of NAFLD, approved pharmacological treatment is lacking. As an inhibitor of androgen receptor (AR), EPI-001 is being explored for the treatment of prostate cancer. This study aimed to investigate the potential of EPI-001 for treating NAFLD in free fatty acids (FFAs)-induced human hepatic cells and high-fat-high-sugar (HFHS)-feeding mice. Our results showed that EPI-001 reduced lipid accumulation in hepatic cells and ameliorated hepatic steatosis in mouse livers. Further exploration suggested that the effect of EPI-001 was associated with CYP2E1-mediated reduction of reactive oxygen species (ROS). This provides encouraging evidence for further studies on EPI-001 therapy for NAFLD.

[1]  F. Carrilho,et al.  Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients. , 2022, Metabolic syndrome and related disorders.

[2]  E. Schiff,et al.  Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial , 2021, Hepatology.

[3]  Xiumei Gao,et al.  New insight and potential therapy for NAFLD: CYP2E1 and flavonoids. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  F. Kuchenbauer,et al.  Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis , 2020, PloS one.

[5]  Hongliang Li,et al.  Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. , 2020, Free radical biology & medicine.

[6]  B. Tabakoff,et al.  Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research , 2020, Biomedicines.

[7]  F. Gonzalez,et al.  PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice , 2020, International journal of molecular sciences.

[8]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[9]  Zhenzhou Jiang,et al.  Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice , 2019, Phytotherapy research : PTR.

[10]  B. Ren,et al.  Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1. , 2019, Journal of oleo science.

[11]  R. Vettor,et al.  Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease , 2019, International journal of molecular sciences.

[12]  M. Azarbayjani,et al.  Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation , 2019, European journal of sport science.

[13]  B. Ren,et al.  Hepatoprotective Effect of Loquat Leaf Flavonoids in PM2.5-Induced Non-Alcoholic Fatty Liver Disease via Regulation of IRs-1/Akt and CYP2E1/JNK Pathways , 2018, International journal of molecular sciences.

[14]  A. Federico,et al.  Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease , 2018, Oxidative medicine and cellular longevity.

[15]  H. Zischka,et al.  Mitochondria in non-alcoholic fatty liver disease. , 2018, The international journal of biochemistry & cell biology.

[16]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[17]  A. Lonardo,et al.  NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk , 2017, Advances in Therapy.

[18]  M. Cheng,et al.  The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α , 2017, Nutrients.

[19]  Yoosoo Chang,et al.  Waist Gain Is Associated with a Higher Incidence of Nonalcoholic Fatty Liver Disease in Korean Adults: A Cohort Study , 2016, PloS one.

[20]  Qiyang Shou,et al.  Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis. , 2016, The Journal of endocrinology.

[21]  C. Byrne,et al.  Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[22]  S. Baker,et al.  Induction of CYP2E1 in non-alcoholic fatty liver diseases. , 2015, Experimental and molecular pathology.

[23]  M. Milowsky,et al.  Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance , 2015, Clinical pharmacology and therapeutics.

[24]  Mary E Rinella,et al.  Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.

[25]  J. Stasch,et al.  Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue , 2015, BMC Pharmacology and Toxicology.

[26]  Giulio Marchesini,et al.  Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[27]  G. Raj,et al.  EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer , 2015, Oncotarget.

[28]  T. Mello,et al.  Pathogenesis of alcoholic liver disease: role of oxidative metabolism. , 2014, World journal of gastroenterology.

[29]  L. Leggio,et al.  Pharmacotherapy for alcoholic patients with alcoholic liver disease. , 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[30]  Jayoung Kim,et al.  MicroRNA-185 and 342 Inhibit Tumorigenicity and Induce Apoptosis through Blockade of the SREBP Metabolic Pathway in Prostate Cancer Cells , 2013, PloS one.

[31]  R. Andersen,et al.  An androgen receptor N-terminal domain antagonist for treating prostate cancer. , 2013, The Journal of clinical investigation.

[32]  F. Gonzalez,et al.  Sex steroid hormones regulate constitutive expression of Cyp2e1 in female mouse liver. , 2013, American journal of physiology. Endocrinology and metabolism.

[33]  M. Başaranoǧlu,et al.  From fatty liver to fibrosis: a tale of "second hit". , 2013, World journal of gastroenterology.

[34]  N. Nieto,et al.  CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. , 2013, Journal of hepatology.

[35]  Z. Halpern,et al.  Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. , 2012, Journal of hepatology.

[36]  B. Fromenty,et al.  Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. , 2011, Clinics and research in hepatology and gastroenterology.

[37]  David E. Williams,et al.  Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. , 2010, Cancer cell.

[38]  I. Smith,et al.  ATP consumption by sarcoplasmic reticulum Ca2+ pumps accounts for 50% of resting metabolic rate in mouse fast and slow twitch skeletal muscle. , 2010, American journal of physiology. Cell physiology.

[39]  David E. Williams,et al.  Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. , 2008, Organic letters.

[40]  A. Cederbaum,et al.  Cytochrome P450 2E1 contributes to ethanol‐induced fatty liver in mice , 2008, Hepatology.

[41]  A. Lonardo,et al.  'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. , 2006, Journal of hepatology.

[42]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[43]  M. Saboorian,et al.  Ethnic Differences in the Prevalence of Cryptogenic Cirrhosis , 2004, American Journal of Gastroenterology.

[44]  Hua Liu,et al.  Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. , 2003, Kidney international.

[45]  C. Day,et al.  Non‐alcoholic steatohepatitis: Definitions and pathogenesis , 2002, Journal of gastroenterology and hepatology.

[46]  A. Sanyal,et al.  AGA technical review on nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[47]  S. Friedman,et al.  Cytochrome P450 2E1-derived Reactive Oxygen Species Mediate Paracrine Stimulation of Collagen I Protein Synthesis by Hepatic Stellate Cells* , 2002, The Journal of Biological Chemistry.

[48]  K. Woodcroft,et al.  The alcohol-inducible form of cytochrome P450 (CYP2E1): Role in toxicology and regulation of expression , 2000, Archives of pharmacal research.

[49]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[50]  V. Wong,et al.  Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. , 2015, Journal of hepatology.

[51]  S. French The importance of CYP2E1 in the pathogenesis of alcoholic liver disease and drug toxicity and the role of the proteasome. , 2013, Sub-cellular biochemistry.